↑ Rising
Business
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Biotech stock Q32 surges 60% after promising alopecia trial results spark JAK inhibitor rivalry
Phase 2 Trial
1 trends tracked about this subject — the full history, oldest to newest below.